The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -692 | -1,529 |
| Share based compensation | 163 | 360 |
| Loss on settlement of common stock warrant liabilities | 0 | 0 |
| Change in fair value of warrant liabilities | 2 | -16 |
| Common stock, issued to fortress, value | 0 | 55 |
| Issuance of stock under founders agreement | 0 | 0 |
| Receivable per license termination and transfer agreement | - | 800 |
| Gain on repurchase of common stock held by annji | 0 | 4 |
| Prepaid expenses and other current assets | -19 | -43 |
| Accounts payable and accrued expenses-Nonrelated Party | -73 | 298 |
| Accounts payable and accrued expenses-Related Party | 164 | 231 |
| Net cash used in operating activities | 383 | -1,362 |
| Proceeds from atm sales of common stock, net of issuance costs | 0 | 2,094 |
| Exercise of warrants | 0 | 0 |
| Warrant transaction costs | 0 | 0 |
| Net cash provided by financing activities | 0 | 2,094 |
| Net change in cash and cash equivalents | 383 | 732 |
| Cash and cash equivalents at beginning of period | 2,594 | - |
| Cash and cash equivalents at end of period | 3,709 | - |
AVENUE THERAPEUTICS, INC. (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI)